Charles Bennett to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Charles Bennett has written about Leukemia, Myeloid, Acute.
Connection Strength
1.165
-
Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res. 2016 May; 44:61-4.
Score: 0.472
-
Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making? Drugs Aging. 2003; 20(7):479-83.
Score: 0.189
-
Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymphoma. 2000 Mar; 37(1-2):65-70.
Score: 0.155
-
Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol. 1999 Feb; 10(2):177-82.
Score: 0.144
-
Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest. 1997; 15(3):227-36.
Score: 0.125
-
Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007 Aug; 40(3):185-92.
Score: 0.064
-
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 01; 24(19):3187-205.
Score: 0.015